Lista de obras -

6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance

artículo científico publicado en 2006

A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.

artículo científico publicado en 2005

Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

artículo científico publicado en 2006

Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma

artículo científico publicado en 2004

Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature

artículo científico publicado en 2010

Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis

scientific article published on 01 July 2002

Bone marrow angiogenesis in multiple myeloma: effect of therapy

article

Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis

artículo científico publicado en 2002

Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma

artículo científico publicado en 2005

Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma

artículo científico publicado en 2010

Clinical course of patients with relapsed multiple myeloma

artículo científico publicado en 2004

Clinical implication of centrosome amplification in plasma cell neoplasm

artículo científico publicado en 2005

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

artículo científico publicado en 2005

Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.

artículo científico publicado en 2009

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

artículo científico publicado en 2003

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

artículo científico publicado en 2005

Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial

artículo científico publicado en 2005

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

artículo científico publicado en 2002

Conflicts of interest, authorship, and disclosures in industry-related scientific publications

artículo científico publicado en 2010

Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression

article

Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines

artículo científico publicado en 2010

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

artículo científico publicado en 2011

Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie

artículo científico publicado en 2010

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system

artículo científico publicado en 2005

Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma

artículo científico publicado en 2006

Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia

artículo científico publicado en 2009

Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1.

artículo científico publicado en 2006

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter ⬇️

artículo científico publicado el 6 de noviembre de 2003

Immunoglobulin D amyloidosis: a distinct entity

artículo científico publicado en 2011

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

artículo científico publicado en 2009

Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma

artículo científico publicado en 2013

Improved survival in multiple myeloma and the impact of novel therapies

artículo científico publicado en 2007

Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component

artículo científico publicado en 2009

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients

artículo científico publicado en 2009

Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial

artículo científico publicado en 2011

Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial

artículo científico publicado en 2012

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

artículo científico publicado en 2007

Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma

artículo científico publicado en 2010

Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis

artículo científico publicado en 2008

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

scientific article published on December 2009

Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma

artículo científico publicado en 2006

Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation

article

Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling

article

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

artículo científico publicado en 2008

Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma

artículo científico publicado en 2007

Oncolytic measles virus targets high CD46 expression on multiple myeloma cells

artículo científico publicado en 2006

POEMS syndrome: definitions and long-term outcome

artículo científico publicado en 2002

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

artículo científico publicado en 2009

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

artículo científico publicado en 2011

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

artículo científico publicado en 2003

Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance

article

Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia

artículo científico publicado en 2006

Prognostic value of angiogenesis in solitary bone plasmacytoma

artículo científico publicado en 2002

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

artículo científico publicado en 2004

Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score

artículo científico publicado en 2011

Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma

artículo científico publicado en 2003

Review of 1027 patients with newly diagnosed multiple myeloma

artículo científico publicado en 2003

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

artículo científico publicado en 2012

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

artículo científico publicado en 2004

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study

artículo científico publicado en 2004

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

artículo científico publicado en 2006

The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome

scientific article published on 31 August 2011

Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.

artículo científico publicado en 2009

Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement

artículo científico publicado en 2007

Trends and outcomes of modern staging of solitary plasmacytoma of bone

artículo científico publicado en 2012

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications

artículo científico publicado en 2006

Lista de obras de

6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance

A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.

Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma

Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature

Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis

Bone marrow angiogenesis in multiple myeloma: effect of therapy

Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis

Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma

Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma

Clinical course of patients with relapsed multiple myeloma

Clinical implication of centrosome amplification in plasma cell neoplasm

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

Conflicts of interest, authorship, and disclosures in industry-related scientific publications

Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression

Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system

Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma

Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia

Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1.

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter ⬇️

Immunoglobulin D amyloidosis: a distinct entity

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma

Improved survival in multiple myeloma and the impact of novel therapies

Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients

Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial

Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma

Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma

Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation

Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma

Oncolytic measles virus targets high CD46 expression on multiple myeloma cells

POEMS syndrome: definitions and long-term outcome

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance

Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia

Prognostic value of angiogenesis in solitary bone plasmacytoma

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score

Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma

Review of 1027 patients with newly diagnosed multiple myeloma

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome

Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.

Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement

Trends and outcomes of modern staging of solitary plasmacytoma of bone

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications